Articles tagged with Kidney Cancer
Researchers at Dana-Farber Cancer Institute found that cabozantinib exceeded sunitinib in progression-free survival and overall response rates for patients with metastatic kidney cancer. The study showed a 20% lower risk of death associated with cabozantinib treatment.
A successful trial shows that taking oral tablet Sunitinib for one year reduces the likelihood of kidney cancer returning for patients following removal of the kidney. The treatment improves disease-free survival and reduces the risk of relapse by 40-50% compared to placebo.
A phase III trial has met its primary endpoint, demonstrating improved disease-free survival with sunitinib in high-risk renal cell carcinoma patients after nephrectomy. The treatment showed a significantly longer disease-free survival of 6.8 years compared to 5.6 years with placebo.
Cabozantinib significantly improves progression-free survival and response rate in patients with intermediate or poor-risk clear-cell metastatic renal cell carcinoma compared to sunitinib. The study also found a higher objective response rate in the cabozantinib arm.
Researchers are investigating the role of SLC13A3, a likely tumor suppressor gene, in kidney cancer. They hope to understand why its expression is suppressed in African American patients and explore its potential as a therapeutic target.
Researchers at UT Southwestern Medical Center have developed a new class of HIF-2 inhibitors that control cancer in half of the tumors tested in mice. The therapy is more active and better tolerated than existing treatments like sunitinib, offering new hope for patients with kidney cancer.
Researchers found that overweight patients with metastatic kidney cancer had significantly longer survival and decreased risk of death compared to normal-weight counterparts. FASN gene expression was also found to be decreased in obese patients, which could explain their better treatment outcomes.
A study published in Nature found that excess fumarate resulting from enzyme loss leads to epigenetic changes promoting epithelial-to-mesenchymal transition, a process driving tumor metastasis. This understanding may provide key strategies for cancer therapy targeting metastasis caused by fumarate accumulation.
A new study has identified gene expression profiles in renal cell carcinoma patients that are less likely to respond to the immunotherapy nivolumab. The study found that tumors with higher levels of metabolism-related genes were more likely to resist treatment and did not benefit from nivolumab, which targets PD-L1 protein.
A recent study published in The Lancet Oncology found that adults with slow-growing kidney cancer can live for months or even years without worsening disease progression through active surveillance. The approach was most successful in patients with limited metastatic disease and fewer risk factors.
The study found that families reported better quality of end-of-life care for patients with cancer or dementia compared to those with end-stage renal disease (ESRD), cardiopulmonary failure, or frailty. Palliative care consultations, do-not-resuscitate orders, and setting of death were associated with improved quality of care.
A new study by Dana-Farber Cancer Institute found that surgery to remove a cancerous kidney can lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer. Patients who undergo the procedure survive for a median period of 17.1 months, compared to 7.7 months for those who don't receive the surgery.
Researchers warn that herbal remedies containing Aristolochia, used for over 2,000 years, can lead to kidney cancer and other health issues in genetically susceptible individuals. The authors call for global action to evaluate the safety and efficacy of botanical products.
A team of researchers at ICIQ has designed and synthesized highly selective and effective Englerin analogues that inhibit the growth of renal cancer cells. The analogues were developed using gold catalysis and exhibited potent anti-cancer activity in cell lines, offering a promising treatment option for patients with kidney cancer.
A study published by the University of Texas M.D. Anderson Cancer Center found a link between obesity and kidney cancer recurrence, with leptin receptors playing a key role in tumor formation. The research suggests that obesity may also impact prognosis for patients with renal cell carcinoma.
A high coronary artery calcium score may signal an increased risk of developing cancer, chronic kidney disease, and chronic obstructive pulmonary disease (COPD). The study found that individuals with high scores had a higher risk of cancer, with a 53% increased risk of developing the disease during follow-up.
Researchers have identified nine distinct subtypes of kidney cancer, each with unique molecular pathways and patient survival outcomes. These findings hold promise for personalized medicine by identifying specific targets for therapies.
A new study published in the Lancet found that sunitinib and sorafenib, widely used targeted therapy drugs for metastatic kidney cancer, have no effect on preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery. The study involved 1,943 patients treated with one year of so...
The International Radiosurgery Oncology Consortium has developed consensus guidelines for the safe implementation and practice of Stereotactic Body Radiation Therapy (SBRT) for primary renal cell carcinoma. SBRT is a non-invasive treatment option with favorable comparisons to existing treatments, offering a cost-effective and widely av...
Researchers found that deprivation of cystine triggers necrosis in renal cell carcinoma cells, leading to cell death and delayed tumor growth. This approach may offer a new therapeutic strategy for treating this aggressive form of kidney cancer.
A study found that kidney failure patients on dialysis were at high risk of kidney and thyroid cancers, while those post-transplant were at higher risk of non-Hodgkin lymphoma and melanoma. The findings highlight the importance of cancer screening and prevention in these patients.
A new study from MD Anderson Cancer Center finds that high-temperature cooking of meat, particularly barbecuing and pan-frying, increases the risk of renal cell carcinoma. Individuals with certain genetic mutations are more susceptible to this risk, highlighting the importance of reducing meat consumption, especially at high temperatures.
A new study links high-temperature cooking of red and white meat to increased risk of kidney cancer, citing the presence of carcinogenic compounds such as PhIP and MeIQx. The study suggests that reducing meat consumption, especially when cooked at high temperatures, may help mitigate this risk.
A new clinical trial has found that cabozantinib, a second-line therapy, controls the growth of advanced kidney cancer more effectively than everolimus. The results show improved progression-free survival and lower tumor growth rates, indicating potential for prolonged survival.
The National Cancer Institute has awarded BIDMC a five-year, $11.3 million grant renewal to continue its leadership in a multi-center kidney cancer research consortium. This funding will support four research projects focused on targeting critical molecular pathways and developing effective treatment combinations.
Results from the METEOR trial show that cabozantinib improves progression-free and overall survival in patients with advanced clear cell kidney cancer, with a median progression-free survival of 7.4 months compared to 3.8 months for everolimus.
Researchers at the University of Texas MD Anderson Cancer Center demonstrated a significant median overall survival benefit with nivolumab, increasing it to 25 months compared to 19.6 months for everolimus. The study also showed a higher objective response rate and fewer treatment-related adverse events with nivolumab.
The CheckMate 025 phase III clinical trial shows that nivolumab significantly prolongs survival in patients with advanced kidney cancer, regardless of PD-L1 expression. The study found a median overall survival of 25 months for nivolumab-treated patients compared to 19.6 months for those treated with everolimus.
A new metal-based compound, Compound 5, has been developed to destroy kidney cancer cells while leaving normal cells unharmed. The compound, which incorporates both titanium and gold, has shown excellent promise in pre-clinical models, outperforming the FDA-approved drug Cisplatin.
Scientists at University of Texas MD Anderson Cancer Center identified EMT as a potential therapeutic target for reversing kidney disease and fibrosis. The study showed that inhibiting EMT in tubular epithelial cells can restore their health and function.
Surgeons report positive outcomes in robotic IVC thrombectomy for renal cancer patients with Level III thrombus. Eight out of nine patients show no evidence of disease after follow-up, with significant advancements in operating room times and blood loss.
Researchers at Mayo Clinic have identified a new epigenomic block that could help stop the progression of many late-stage cancers. This discovery has the potential to improve diagnosis and treatment of advanced disease across various cancer types.
A study published in Cancer Research reveals how renal cell carcinoma reprogrammes its environment to suppress the immune response. The research found that cancer grade significantly impacts this process, with higher-grade cancers exhibiting more aggressive remodelling.
Physicians at UT Southwestern have successfully treated a rare and often deadly complication of kidney cancer using stereotactic body radiation therapy, with similar survival rates to surgery. The innovative approach shows promise as an alternative treatment option for patients resistant to traditional therapies.
Researchers developed a non-invasive method to screen for kidney cancer by measuring protein biomarkers in urine, achieving over 95% accuracy. The findings suggest the potential for an easy-to-use screening test, similar to mammograms or colonoscopies, to identify patients with kidney cancer at early stages.
A study by NCCS reveals a new attenuated-dose regimen of sunitinib improves patient quality of life and reduces treatment costs for Asian patients with metastatic renal cell carcinoma. The median overall survival rate increased to 27.4 months, reducing toxicities by 30% compared to the conventional dosing.
Researchers at the University of Leeds have discovered a rare African bush that may help treat kidney cancer. The Phyllanthus engleri plant contains a chemical called Englerin A, which activates specific proteins in renal cancer cells, leading to their death.
A new study identified older white males with advanced bladder cancer as a high-risk group for suicide. Researchers found that these patients have a higher suicide risk compared to those with other genitourinary cancers.
A higher intake of lycopene among postmenopausal women may lower the risk of renal cell carcinoma by 39%. The study analyzed data from 96,196 women and found a significant association between lycopene intake and reduced kidney cancer risk. Lycopene is a natural antioxidant found in foods like tomatoes and watermelon.
A study by American Chemical Society researchers found that oat-based breakfast cereals exceeded EU standards for ochratoxin A levels in 8% of samples. The findings highlight the need for improved oat production, storage, and processing to protect consumer health.
A phase three trial found that using sunitinib or sorafenib after surgery did not reduce recurrence in high-risk renal cell carcinoma patients, compared to standard care. The study, E2805, involved 1943 patients and demonstrated no significant differences in disease-free survival or overall survival between treatment groups.
Patients with locally advanced kidney cancer did not experience improved outcomes from adjuvant treatment with sorafenib or sunitinib. The average disease recurrence period was similar between those receiving the drugs and those on placebo, suggesting that these treatments may not be beneficial for this patient group.
Scientists at Lund University have discovered a way to identify the most malignant tumours in children by studying genetic micro-variation. The study found that the degree of genetic variation between cells is linked to the severity of cancer in children, making it a potential marker for predicting treatment outcomes.
Close monitoring of small renal tumors can be an alternative to surgery, with low rates of tumor growth or death observed. The study's findings suggest that actively monitoring these tumors in high-risk patients may prove safer than immediate surgery.
A study published in Medical Care found that hospitals adopting surgical robots performed more partial nephrectomies, an underutilized procedure that preserves functioning kidney tissue. The increased use of partial nephrectomy may be attributed to improved magnification and manual dexterity provided by the robots.
A new study shows that hospitals adopting robotic surgery between 2001-2004 performed partial nephrectomies more frequently, preserving organs for kidney cancer patients. This increase in partial nephrectomy rates is attributed to greater institutional experience with robotic surgery.
Patients with advanced papillary kidney cancer respond well to a combination of bevacizumab and erlotinib, with excellent response rates and long-lasting results. The treatment shows promise for patients with hereditary leiomyomatosis and renal cell cancer (HLRCC) who have poor prognosis.
Researchers at UT Southwestern Medical Center have identified over 3,000 new gene mutations involved in certain kidney cancers. The study reveals how these mutations transform a normal kidney cell into a cancer cell through the interaction of two genes, VHL and BAP1.
Researchers found HIV-infected adults diagnosed with kidney failure six months younger than the general population, while heart attack and cancer diagnoses were similar. The study suggests successful treatments are helping HIV-infected persons achieve similar longevity.
Researchers have discovered a new target for treating kidney cancer by targeting the Transient Receptor Potential Melastatin 3 channel. This channel promotes tumor growth and stimulates autophagy in cancer cells.
A new study by CAGEKID consortium reveals a strong connection between kidney cancer and aristolochic acid, an ingredient in herbal remedies. The research found that genetic changes associated with this type of cancer were observed in patients from Romania with high frequency, suggesting exposure to aristolochic acid as a potential cause.
A new genetic study reveals a link between exposure to aristolochic acid and incidence of clear-cell renal cell carcinoma, the most common form of kidney cancer. The research, conducted on 94 patients from Europe, suggests that this plant compound may be a significant risk factor for kidney cancer, particularly in Central Europe.
A team of scientists sequenced chromophobe renal cell carcinoma tumors and found unique alterations involving telomerase, a gene that plays a critical role in cell division. This discovery provides new clues about the disease's biology and may lead to the development of targeted therapies for this rare type of kidney cancer.
A large study published in European Urology has found that needle-guided tumor destruction procedures, such as partial nephrectomy and radiofrequency ablation, offer near equivalent lengths of local cancer control compared to surgery for patients with small kidney cancer tumors.
Researchers have developed a first-of-its-kind molecular test kit that can predict treatment and survival outcomes in kidney cancer patients based on their tumor profile. The assay was able to distinguish patients into groups with different survival and treatment outcomes, allowing for more educated choices in treatment options.
A study published in Nature Communications found that pseudogene expression profiles can help explain how cancer occurs and aid in discovering new biomarkers. This knowledge is crucial for developing targeted therapies and predicting patient outcomes.
Researchers have uncovered 31 genes crucial to the development, growth, and spread of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. The study found eight previously unlinked genes and six unknown to any cancer type, highlighting potential new therapeutic targets.
Researchers at Mayo Clinic discovered that the NPTX2 gene is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer. The study reveals that NPTX2 plays a key role in this cancer type, which is resistant to chemotherapy and has a low five-year overall survival rate.
New research links low blood cholesterol to more advanced tumor stages and reduced cancer survival rates in kidney cancer patients. High cholesterol levels are associated with a lower risk of death from the disease, suggesting a potential new prognostic tool for monitoring patient outcomes.
Chronic kidney disease is associated with a higher risk of developing renal and urothelial cancers. A recent study found that patients with reduced glomerular filtration rates were more likely to develop these types of cancer, particularly those with severe chronic kidney disease.